259 related articles for article (PubMed ID: 21389097)
1. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.
Fransen MF; Sluijter M; Morreau H; Arens R; Melief CJ
Clin Cancer Res; 2011 Apr; 17(8):2270-80. PubMed ID: 21389097
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer.
Fransen MF; Cordfunke RA; Sluijter M; van Steenbergen MJ; Drijfhout JW; Ossendorp F; Hennink WE; Melief CJ
Vaccine; 2014 Mar; 32(15):1654-60. PubMed ID: 24508038
[TBL] [Abstract][Full Text] [Related]
3. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.
van Mierlo GJ; den Boer AT; Medema JP; van der Voort EI; Fransen MF; Offringa R; Melief CJ; Toes RE
Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5561-6. PubMed ID: 11929985
[TBL] [Abstract][Full Text] [Related]
4. Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects.
Welniak LA; Shorts L; Subleski J; Blazar BR; Wiltrout RH; Murphy WJ
Biol Blood Marrow Transplant; 2004 Aug; 10(8):534-9. PubMed ID: 15282531
[TBL] [Abstract][Full Text] [Related]
5. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.
Sandin LC; Orlova A; Gustafsson E; Ellmark P; Tolmachev V; Tötterman TH; Mangsbo SM
Cancer Immunol Res; 2014 Jan; 2(1):80-90. PubMed ID: 24778163
[TBL] [Abstract][Full Text] [Related]
6. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal.
Lee H; Park HJ; Sohn HJ; Kim JM; Kim SJ
J Surg Res; 2011 Jul; 169(1):e43-50. PubMed ID: 21571303
[TBL] [Abstract][Full Text] [Related]
8. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
Kikuchi T; Miyazawa N; Moore MA; Crystal RG
Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
[TBL] [Abstract][Full Text] [Related]
9. Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects.
Fransen MF; van der Sluis TC; Ossendorp F; Arens R; Melief CJ
Clin Cancer Res; 2013 Oct; 19(19):5381-9. PubMed ID: 23788581
[TBL] [Abstract][Full Text] [Related]
10. Eradication of established tumors in mice by a combination antibody-based therapy.
Uno T; Takeda K; Kojima Y; Yoshizawa H; Akiba H; Mittler RS; Gejyo F; Okumura K; Yagita H; Smyth MJ
Nat Med; 2006 Jun; 12(6):693-8. PubMed ID: 16680149
[TBL] [Abstract][Full Text] [Related]
11. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells.
Honeychurch J; Glennie MJ; Illidge TM
Cancer Res; 2005 Aug; 65(16):7493-501. PubMed ID: 16103104
[TBL] [Abstract][Full Text] [Related]
13. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy using in vitro genetically modified targeted dendritic cells.
Wei H; Wang H; Lu B; Li B; Hou S; Qian W; Fan K; Dai J; Zhao J; Guo Y
Cancer Res; 2008 May; 68(10):3854-62. PubMed ID: 18483270
[TBL] [Abstract][Full Text] [Related]
16. The use of agonistic anti-CD40 therapy in treatments for cancer.
Khong A; Nelson DJ; Nowak AK; Lake RA; Robinson BW
Int Rev Immunol; 2012 Aug; 31(4):246-66. PubMed ID: 22804570
[TBL] [Abstract][Full Text] [Related]
17. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.
Diehl L; den Boer AT; Schoenberger SP; van der Voort EI; Schumacher TN; Melief CJ; Offringa R; Toes RE
Nat Med; 1999 Jul; 5(7):774-9. PubMed ID: 10395322
[TBL] [Abstract][Full Text] [Related]
18. Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205(+) dendritic cells.
Moriya K; Wakabayashi A; Shimizu M; Tamura H; Dan K; Takahashi H
Cancer Immunol Immunother; 2010 Jul; 59(7):1083-95. PubMed ID: 20221597
[TBL] [Abstract][Full Text] [Related]
19. Agonistic anti-CD40 antibody therapy is effective against postoperative cancer recurrence and metastasis in a murine tumor model.
Khong A; Brown MD; Vivian JB; Robinson BW; Currie AJ
J Immunother; 2013 Sep; 36(7):365-72. PubMed ID: 23924788
[TBL] [Abstract][Full Text] [Related]
20. Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer.
Rahimian S; Fransen MF; Kleinovink JW; Amidi M; Ossendorp F; Hennink WE
Biomaterials; 2015 Aug; 61():33-40. PubMed ID: 25993015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
